MA39549A1 - Comprimé dispersible de misoprostol - Google Patents

Comprimé dispersible de misoprostol

Info

Publication number
MA39549A1
MA39549A1 MA39549A MA39549A MA39549A1 MA 39549 A1 MA39549 A1 MA 39549A1 MA 39549 A MA39549 A MA 39549A MA 39549 A MA39549 A MA 39549A MA 39549 A1 MA39549 A1 MA 39549A1
Authority
MA
Morocco
Prior art keywords
misoprostol
dispersible
tablet
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
MA39549A
Other languages
English (en)
Other versions
MA39549B1 (fr
Inventor
Sekar Selvaraj
Baskar Elumalai
Malaiarasan Arunachalam
Prabhakaran Venugopal
Original Assignee
Azanta Danmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azanta Danmark As filed Critical Azanta Danmark As
Priority claimed from PCT/DK2015/050216 external-priority patent/WO2016004960A2/fr
Publication of MA39549A1 publication Critical patent/MA39549A1/fr
Publication of MA39549B1 publication Critical patent/MA39549B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une formulation pharmaceutique solide comportant du misoprostol ou son sel pharmaceutiquement acceptable. En particulier, l'invention concerne un comprimé dispersible comprenant du misoprostol ou son sel pharmaceutiquement acceptable, procurant d'autres voies d'administration. Ledit comprimé est particulièrement adapté à la maturation du col de l'utérus, l'induction du travail, la prévention et/ou le traitement de l'hémorragie post-avortement ou post-partum.
MA39549A 2014-07-11 2015-07-10 Comprimé dispersible de misoprostol MA39549B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14176821.8A EP2965750B1 (fr) 2014-07-11 2014-07-11 Comprimé dispersible de misoprostol
PCT/DK2015/050216 WO2016004960A2 (fr) 2014-07-11 2015-07-10 Comprimé dispersible de misoprostol

Publications (2)

Publication Number Publication Date
MA39549A1 true MA39549A1 (fr) 2017-12-29
MA39549B1 MA39549B1 (fr) 2019-04-30

Family

ID=51167770

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39549A MA39549B1 (fr) 2014-07-11 2015-07-10 Comprimé dispersible de misoprostol

Country Status (13)

Country Link
EP (2) EP2965750B1 (fr)
CY (1) CY1119193T1 (fr)
DK (1) DK2965750T3 (fr)
ES (1) ES2645481T3 (fr)
HR (1) HRP20171220T1 (fr)
HU (1) HUE033619T2 (fr)
LT (1) LT2965750T (fr)
MA (1) MA39549B1 (fr)
PL (1) PL2965750T3 (fr)
PT (1) PT2965750T (fr)
RS (1) RS56468B1 (fr)
SI (1) SI2965750T1 (fr)
SM (1) SMT201700398T1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125450A1 (fr) 2005-05-26 2006-11-30 Atef Mohammed Mostafa Darwish Suppositoires rectaux et vaginaux contenant du misoprostol
US20060286172A1 (en) 2005-06-03 2006-12-21 Anu Mahashabde Pharmaceutical compositions comprising prostanoid-receptor agonists and methods of making and using the same
WO2007035954A2 (fr) 2005-09-23 2007-03-29 Duramed Pharmaceuticals, Inc. Comprimes vaginaux comportant du misoprostol et leurs procedes de fabrication et d'utilisation
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
WO2009154810A2 (fr) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Systèmes d'administration de multiples principes actifs
CN102697746B (zh) * 2012-06-11 2014-03-19 广州朗圣药业有限公司 一种快速融变的米索前列醇阴道用组合物及其制备方法和应用
EP2877181A1 (fr) 2012-07-26 2015-06-03 Ferring BV Composition de misoprostol
CN102872024B (zh) * 2012-09-28 2015-06-17 天津市聚星康华医药科技有限公司 口腔内使用的米索前列醇药物组合物
CN103340837B (zh) * 2013-07-08 2018-04-27 天津市聚星康华医药科技有限公司 一种米索前列醇阴道泡腾片及其制备方法

Also Published As

Publication number Publication date
HUE033619T2 (en) 2017-12-28
EP2965750A1 (fr) 2016-01-13
PL2965750T3 (pl) 2018-01-31
RS56468B1 (sr) 2018-01-31
EP3238715A1 (fr) 2017-11-01
MA39549B1 (fr) 2019-04-30
PT2965750T (pt) 2017-10-03
EP2965750B1 (fr) 2017-08-02
SMT201700398T1 (it) 2017-09-07
LT2965750T (lt) 2017-09-25
SI2965750T1 (sl) 2017-11-30
ES2645481T3 (es) 2017-12-05
DK2965750T3 (en) 2017-10-16
HRP20171220T1 (hr) 2017-11-03
CY1119193T1 (el) 2018-02-14

Similar Documents

Publication Publication Date Title
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA41010A (fr) Compositions comprenant des souches bactériennes
MA41013A (fr) Compositions comprenant des souches bactériennes
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
MX2015003229A (es) Composiciones que comprenden mezclas de alcanos semifluorados.
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EP3238745A4 (fr) Agent inducteur de mort cellulaire, agent cytostatique, et composition pharmaceutique pour le traitement de maladies provoquées par une croissance cellulaire anormale
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MX2020012800A (es) Cannabinoides y usos de los mismos.
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP3804736A4 (fr) Composition pharmaceutique comprenant des cellules souches mésenchymateuses en tant qu'ingrédient efficace pour la prévention ou le traitement d'une maladie inflammatoire
EA202190510A1 (ru) Новое лекарственное средство для лечения воспалительной болезни кишечника
MA50383B1 (fr) Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos
ZA201906153B (en) Pharmaceutical compositions for combination therapy
MA39448A1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA39549B1 (fr) Comprimé dispersible de misoprostol
EP4356915A3 (fr) Formulation de suppositoire à base d'acétate d'hydrocortisone pour le traitement d'une maladie
EA201791686A1 (ru) Клизма для ректального введения
EA201692536A1 (ru) Диспергируемая таблетка мизопростола
JO3321B1 (ar) قرص قابل للتشتت من ميزوبروستول
MA41059A (fr) Compositions comprenant des souches bactériennes